Status:
COMPLETED
An Observational Study Called ROVER to Learn More About How Well Vericiguat Works in People Who Were Newly Treated With Vericiguat in Routine Medical Care in Germany
Lead Sponsor:
Bayer
Conditions:
Chronic Heart Failure With Reduced Ejection Fraction
Eligibility:
All Genders
18+ years
Brief Summary
This is an observational study in which data already collected from people treated with vericiguat are studied. In observational studies, only observations are made without participants receiving any...
Eligibility Criteria
Inclusion
- Patients with an initial prescription of Vericiguat (index date) according to ATC Code C01DX22.
- At least 18 years or older on the initial prescription of Vericiguat.
Exclusion
- No exclusion criteria for any population will be applied.
Key Trial Info
Start Date :
July 5 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 31 2025
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06486844
Start Date
July 5 2024
End Date
August 31 2025
Last Update
September 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bayer
Wuppertal, Germany, 42096